LABORATORY CORP OF AMERICA HOLDINGS
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Index
Item 16. FORM 10-K SUMMARY
None.
Index
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
| By: | /s/ ADAM H. SCHECHTER | ||
| Adam H. Schechter | |||
| President and Chief Executive Officer | |||
| Dated: | February 26, 2024 | ||
|---|---|---|---|
Index
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant on February 26, 2024 in the capacities indicated.
| Signature | Title |
|---|---|
| /s/ ADAM H. SCHECHTER | President and Chief Executive Officer |
| Adam H. Schechter | (Principal Executive Officer) |
| /s/ GLENN A. EISENBERG | Executive Vice President, Chief Financial Officer |
| Glenn A. Eisenberg | (Principal Financial Officer) |
| /s/ PETER J. WILKINSON | Senior Vice President and Chief Accounting Officer |
| Peter J. Wilkinson | (Principal Accounting Officer) |
| * | Director |
| Kerrii B. Anderson | |
| * | Director |
| Jean-Luc Bélingard | |
| * | Director |
| Jeffrey A. Davis | |
| * | Director |
| D. Gary Gilliland, M.D., Ph.D. | |
| * | Director |
| Kirsten M. Kliphouse | |
| * | Director |
| Garheng Kong, M.D., Ph.D. | |
| * | Director |
| Peter M. Neupert | |
| * | Director |
| Richelle Parham | |
| * | Director |
| Paul B. Rothman, M. D. | |
| * | Director |
| Kathryn E. Wengel | |
| * | Director |
| R. Sanders Williams, M.D. | |
- Sandra van der Vaart, by her signing her name hereto, does hereby sign this Annual Report on behalf of the directors of the Registrant after whose typed names asterisks appear, pursuant to powers of attorney duly executed by such directors and filed with the Securities and Exchange Commission.
| By: | /s/ Sandra van der Vaart |
|---|---|
| Sandra van der Vaart | |
| Attorney-in-fact |
Index
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |||
|---|---|---|---|
| Report of Independent Registered Public Accounting Firm Deloitte & Touche LLP | PCAOB ID No. | 34 | F-2 |
| Consolidated Financial Statements: | |||
| Consolidated Balance Sheets | F-6 | ||
| Consolidated Statements of Operations | F-7 | ||
| Consolidated Statements of Comprehensive Earnings | F-8 | ||
| Consolidated Statements of Changes in Shareholders' Equity | F-9 | ||
| Consolidated Statements of Cash Flows | F-10 | ||
| Notes to Consolidated Financial Statements | F-11 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.